If you have been reading about triple agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-14. Numbers and descriptions here follow the published literature rather than marketing material.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
According to Zaid, the followers of Houthi's insistence on chanting the slogans attracted the authorities' attention, further increasing government worries over the extent of the Houthi movement's influence. "The security authorities thought that if today the Houthis chanted 'Death to America', tomorrow they could be chanting 'Death to the president [of Yemen]'". In 2004, 800 BY supporters were arrested in Sanaa. President Ali Abdullah Saleh then invited Hussein al-Houthi to a meeting in Sanaa, but Hussein declined. On 18 June, Saleh sent government forces to arrest Hussein. Hussein responded by launching an insurgency against the central government but was killed on 10 September. The insurgency continued intermittently until a ceasefire agreement was reached in 2010. During this prolonged conflict, the Yemeni army and air force were used to suppress the Houthi rebellion in northern Yemen. The Saudis joined these anti-Houthi campaigns, but the Houthis won against both Saleh and the Saudi army. According to the Brookings Institution, this particularly humiliated the Saudis, who spent tens of billions of dollars on their military. The Houthis participated in the 2011 Yemeni Revolution, as well as the ensuing National Dialogue Conference (NDC). However, they rejected the provisions of the November 2011 Gulf Cooperation Council deal on the ground that "it divide[d] Yemen into poor and wealthy regions" and also in response to the assassination of their representative at NDC. As the revolution went on, Houthis gained control of greater territory.
These medications may suppress appetite, make food taste different, or affect how nutrients are absorbed, making it even less likely seniors will get the required nutrients. 8% of seniors suffer from hyponatremia, although it is unclear how much of that is due to "tea and toast" diets. The prevalence of hyponatremia in the elderly population may be even higher in health care settings. Hyponatremia is believed to arise as a result of a diet poor in salt and protein with large water intake in combination with a low glomerular filtration rate (GFR). The low GFR causes a lowered rate of osmole excretion, and an increase in the amount of water reabsorbed; thus, hyponatremia occurs when the amount of water intake exceeds the renal water excretion capacity. Medications, such as thiazides and antidepressants, may exacerbate symptoms of hyponatremia.
The new name was prompted by his English wife at the time, Jeanie, who told him to drink a cup of tea she had made for him before it became "stone cold". His new persona was partially inspired by serial killer Richard "the Iceman" Kuklinski. Austin wrestled Vega on Raw to a double countout, before defeating him in his first WrestleMania appearance at WrestleMania XII. At In Your House: Beware of Dog, Austin lost a Caribbean strap match to Vega, with the added stipulation that DiBiase was forced to leave the WWF as a result, leading Austin to quietly vacate the Million Dollar title. DiBiase would later say that nobody foresaw the success Austin would have, and had advised him to ignore the advice given to him by producers and continue what he was doing as success required patience.
E-commerce was supposed to level the playing ground between small and large businesses, but the growth of online organized crime is leading to the opposite effect; large businesses are able to afford more bandwidth (to resist denial-of-service attacks) and superior security. Furthermore, organized crime using the Internet is much harder to trace down for the police (even though they increasingly deploy cybercops) since most police forces and law enforcement agencies operate within a local or national jurisdiction while the Internet makes it easier for criminal organizations to operate across such boundaries without detection. In the past criminal organizations have naturally limited themselves by their need to expand, putting them in competition with each other. This competition, often leading to violence, uses valuable resources such as manpower (either killed or sent to prison), equipment and finances. In the United States, James "Whitey" Bulger, the Irish Mob boss of the Winter Hill Gang in Boston turned informant for the Federal Bureau of Investigation (FBI). He used this position to eliminate competition and consolidate power within the city of Boston which led to the imprisonment of several senior organized crime figures including Gennaro Angiulo, underboss of the Patriarca crime family. Infighting sometimes occurs within an organization, such as the Castellamarese war of 1930–31 and the Boston Irish Mob Wars of the 1960s and 1970s.
One of Jennette's clinical research associates is his daughter, Caroline J. Poulton, who is the Research Program Director for the UNC Kidney Center. They are co-authors on 20 journal articles that focus on various clinical aspects of kidney disease with the goal of improving patient outcomes, such as a study to optimize treatment outcomes for patients with ANCA vasculitis.
Sources: en.wikipedia.org
The protein design conformational space can be represented as a tree, where the protein residues are ordered in an arbitrary way, and the tree branches at each of the rotamers in a residue. Branch and bound algorithms use this representation to efficiently explore the conformation tree: At each branching, branch and bound algorithms bound the conformation space and explore only the promising branches. A popular search algorithm for protein design is the A* search algorithm. A* computes a lower-bound score on each partial tree path that lower bounds (with guarantees) the energy of each of the expanded rotamers. Each partial conformation is added to a priority queue and at each iteration the partial path with the lowest lower bound is popped from the queue and expanded. The algorithm stops once a full conformation has been enumerated and guarantees that the conformation is the optimal. The A* score f in protein design consists of two parts, f=g+h. g is the exact energy of the rotamers that have already been assigned in the partial conformation. h is a lower bound on the energy of the rotamers that have not yet been assigned. Each is designed as follows, where d is the index of the last assigned residue in the partial conformation.
==== Anxiety disorders ==== Tiagabine may be prescribed off-label to treat certain anxiety disorders, such as panic disorder and social anxiety disorder. Tiagabine may be used alongside selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), or benzodiazepines for anxiety. The drug was ineffective for generalized anxiety disorder.
In a 2010 episode of the television series Merlin, Prince Arthur goes on a quest for the trident of the Fisher King, who asks for a magical bracelet in return, which will allow him to finally die. The 2011-2019 series Game of Thrones features a character named Brandon Stark who is injured in his leg and groin area and is unable to walk but is able to foretell the future. In the 2012 arc of the Fables comics, the story of the Fisher King is a plot device driving one of the young protagonists. On the 2013 album Tape Deck Heart by Frank Turner there is a song called "The Fisher King Blues". Patricia A. McKillip's book Kingfisher, published in 2016, is an Arthurian grail quest type of story set in a world "in which the modern lives side-by-side with the mythical", featuring a certain mysterious Kingfisher Inn, the owner of which was wounded in an accident that caused his Inn to lose its once great prosperity. The 2016 video game Dark Souls III features the character Ludleth of Courland, whose design and story are based on the legend of the Fisher King. The Fisher King appears as a fictional king of Anglesey in British author Giles Kristian's 2020 novel Camelot, in which he is the protagonist Galahad's maternal grandfather. Robert Bruton's 2023 historical fiction novel Empire in Apocalypse depicts Roman Emperor Justinian, whose lands are beset by famine and war, as a tragic fisher king figure suffering from plague and unable to put his lands in order. A character called the Fisher King can be found in The Witcher books and video games.
== O == Severo Ochoa (1905–1993). Spanish and American biochemist at New York University, major contributor to elucidating the genetic code. Nobel Prize in Physiology or Medicine (1959). Member Natl. Acad. Sci. USA. Alexander George Ogston FRS (1911–1996). British biochemist at Oxford University, known for the three-point attachment explanation of how an achiral substance can have a chiral product in the tricarboxylate cycle. Reiji Okazaki (1930–1975). Japanese molecular biologist at Nagoya University, known for discovering Okazaki fragments, an essential step for understanding DNA replication. Tsuneko Okazaki (b. 1933). Japanese molecular biologist at Nagoya University, known for discovering Okazaki fragments, an essential step for understanding DNA replication. L'Oréal-UNESCO Award for Women in Science. Joan Oró (1923–2004). Spanish biochemist at the University of Houston. Prominent for studies of the origin of life. Muriel Wheldale Onslow (1880–1932). British biochemist at Cambridge University, pioneer in biochemical genetics who worked on petal colour in flowers. Alexander Oparin, (1894–1980). Soviet biochemist at Moscow State University, known for his theory on the origin of life in coacervates. Full Member of the USSR Academy of Sciences. Mary Osborn (b. 1940). English cell biologist at the University of Göttingen known for developing techniques for determining protein molecular masses. Mary Jane Osborn (1927–2019). American biochemist at the University of Connecticut, who worked on lipopolysaccharides, and discovered the mechanism of action of methotrexate.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.